La vendita allo scoperto per Cabaletta Bio dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Cabaletta Bio. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Cabaletta Bio (NASDAQ:CABA) Azioni, Report sulle vendite allo scoperto

CABALETTA BIO INC

Cabaletta Bio

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Cabaletta Bio Inc

Cabana Target Beta ETF

Cabana Target Drawdown 10 ETF

Cabana Target Leading Sector Moderate ETF

WIIM

BP shares are trading higher after the Wall Street Journal reported Shell is in early talks to acquire the company.

SHEL

Shell shares are trading lower after a Wall Street Journal report said the company is in early talks to acquire BP.

<a href="https://www.wsj.com/business/energy-oil/shell-in-early-talks-to-acquire-rival-bp-2233591a" title="https://www.wsj.com/business/energy-oil/shell-in-early-talks-to-acquire-rival-bp-2233591a">https://www.wsj.com/business/energy-oil/shell-in-early-talks-to-acquire-rival-bp-2233591a</a>

'Shell in Early Talks to Acquire Rival BP; A Deal For Bp, Worth Roughly $80B, Would Be A Landmark Combination Of Two Supermajor Oil Companies' - WSJ

Winnebago Industries shares are trading lower after the company reported Q3 financial results and cut its FY25 guidance below estimates.

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares are hitting new all-time highs on Wednesday. Here&#8217;s a look at what&#8217;s <a href="https://www.benzinga.com/news/space/25/06/46090791/us-tests-radar-that-could-help-trumps-golden-dome-detect-missiles-over-1200-miles-report">fueling the momentum</a>.
What To Know: Palantir shares have risen more than 500% over the past year and are now up approximately 93% year-to-date. 
Much of the momentum has been driven by the company&#8217;s positioning in the AI space.&nbsp;The stock also appeared to get a lift more recently from the Israel-Iran conflict. Palantir has several government contracts and has seen an acceleration since President Donald Trump took office, securing <a href="https://www.benzinga.com/news/contracts/25/05/45702431/palantir-stock-gains-as-trump-expands-companys-role-in-us-government-agencies">more than $113 million</a>&nbsp;in contracts. Palantir was also awarded a $795 million contract modification by the U.S. Army for its Maven Smart System&nbsp;in May.
As defense budgets increasingly incorporate AI, Palantir could be a potential beneficiary of heightened geopolitical tensions. Palantir signed a strategic agreement with the Israeli Defense Ministry to support war efforts last year, <a href="https://www.palantir.com/assets/xrfr7uokpv1b/3MuEeA8MLbLDAyxixTsiIe/9e4a11a7fb058554a8a1e3cd83e31c09/C134184_finaleprint.pdf">per</a> Bloomberg.
Even as Palantir shares continue to climb to new highs, some analysts believe there could be more room to run. Loop Capital analyst Mark Schappel maintained Palantir with a Buy and raised the price target from&nbsp;$130&nbsp;to&nbsp;$155 earlier this month. At the end of May, Wedbush's Dan Ives predicted that Palantir shares will more than triple in two to three years to reach a $1 trillion market cap valuation, or approximately $427 per share.
"[Alex] Karp, he's playing chess, others are playing checkers. And I think you are starting to realize more and more in government, enterprise, and that's why you cannot talk AI revolution without saying Palantir,&#8221; Ives said in a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45655507/tech-analyst-expects-palantir-stock-to-rise-above-400-as-ai-revolution-kicks-into-gear">CNBC</a> interview. 
Palantir has a strong momentum score of 99, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> data. The company beat analyst estimates in the first quarter as U.S. Commercial revenue grew 71% year-over-year and U.S. Government revenue climbed 45%. 
Palantir also guided for second-quarter revenue in the range of $934 million to $938 million versus estimates of $899.12 million, and raised its full-year outlook. The company said in its earnings release that it&#8217;s experiencing &#8220;surging and ferocious growth.&#8221;
PLTR Price Action: Palantir shares traded as high as $147.67 on Wednesday, marking new all-time highs. The stock was up 0.18% at $142.94 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Palantir has an RSI of 66, per Benzinga <a href="https://www.benzinga.com/quote/PLTR">data</a>. A stock is generally considered overbought when its relative strength rises above 70. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46090043/trump-advisor-stephen-miller-reportedly-holds-stake-worth-millions-in-ice-contractor-palantir-he-could-easily-have-a-direct-and-predictable-impact">Trump Advisor Stephen Miller Reportedly Holds Stake Worth Millions In ICE Contractor Palantir: &#8216;He Could Easily&#8230;Have A Direct And Predictable Impact&#8217;</a></li>
</ul>
Photo: slyellow/Shutterstock.

News

Movers

PLTR

Palantir Stock Hits All-Time High: What's Going On?

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is continuing its remarkable run Wednesday, with shares climbing 2.6% to $151.74, near a new all-time high. The stock&#8217;s recent run completes a full recovery from a 17% drop in January, initially sparked by fears that China&#8217;s DeepSeek AI <a href="https://www.benzinga.com/markets/tech/25/06/46062695/nvidia-deepseek-ai-chips-us-china-military-news">could challenge</a> Nvidia&#8217;s market dominance.
What To Know: Nvidia&#8217;s rebound in recent weeks has been fueled by a significant easing in U.S.-China trade tensions and a stellar first-quarter earnings report on May 28. 
The company announced earnings per share of 81 cents on a staggering $44.06 billion in revenue, a 69% year-over-year increase, <a href="https://www.benzinga.com/markets/tech/25/06/46058862/nvidia-intel-chip-stocks-ai-valuation-revenue">blowing past</a> analyst expectations and reaffirming its leadership in the AI chip sector.
Adding to the bullish sentiment, Nvidia&#8217;s stock is on the verge of a &#8220;<a href="https://www.benzinga.com/markets/tech/25/06/46081553/nvidia-stock-forecast-trump-china-golden-cross-ai">golden cross</a>,&#8221; a technical pattern where the 50-day moving average surpasses the 200-day average, often signaling a sustained uptrend. Historically, this pattern has preceded massive rallies in Nvidia&#8217;s stock, with past occurrences leading to triple and even quadruple-digit percentage gains.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/06/46072105/hcltech-amd-partner-to-power-next-gen-enterprise-ai-and-cloud-adoption">HCLTech, AMD Partner To Power Next-Gen Enterprise AI And Cloud Adoption</a>
Despite recent allegations that DeepSeek has been supplying Nvidia&#8217;s advanced chips to China&#8217;s military, circumventing U.S. export controls, investors remain focused on the company&#8217;s explosive growth, which continues to vastly <a href="https://www.benzinga.com/markets/tech/25/06/46058862/nvidia-intel-chip-stocks-ai-valuation-revenue">outpace competitors</a> like Intel Corp.
Analyst Updates: Following its strong earnings report, Wall Street has shown <a href="https://www.benzinga.com/quote/NVDA/analyst-ratings">overwhelming confidence</a> in Nvidia&#8217;s continued growth. In a flurry of updates on May 29, numerous firms reiterated their positive ratings and raised price targets. 
Notably, Truist Securities increased its target to $210, and Rosenblatt lifted its target to $200. The bullish sentiment has continued into June, with Barclays raising its price target to $200 on June 17 while maintaining an &#8220;Overweight&#8221; rating. 
The vast majority of analysts maintain a &#8220;Buy&#8221; or equivalent rating, with many price targets suggesting a potential upside of 15% to over 35% from its current highs.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NVDA has a 52-week high of $153.13 and a 52-week low of $86.62.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/06/46069690/alibaba-accelerates-global-ai-push-targets-overseas-data-centers">Alibaba Accelerates Global AI Push, Targets Overseas Data Centers</a>
<h2 class="wp-block-heading">How To Buy NVDA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in NVIDIA&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

NVDA

Nvidia Stock Soars Near Record High: What's Driving the Rally?

JP Morgan analyst Alexei Gogolev maintains Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) with a Overweight and raises the price target from $271 to $288.

Price Target

Analyst Ratings

GWRE

JP Morgan Maintains Overweight on Guidewire Software, Raises Price Target to $288

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and maintains $17 price target.

Reiteration

BCRX

Needham Reiterates Buy on BioCryst Pharma, Maintains $17 Price Target

Shares of Carnival Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) were trading lower on Wednesday, despite the company on Tuesday reporting <a href="https://www.benzinga.com/markets/earnings/25/06/46076919/carnival-sails-past-q2-estimates-raises-full-year-outlook-on-strong-demand">upbeat fiscal second-quarter results</a>.
The announcement came amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
Goldman Sachs On Carnival
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/647713f84d196600013124ad/lizzie-dove">Analyst Lizzie Dove</a> maintained a Buy rating, while raising the price target from $31 to $33.
Carnival's fiscal second-quarter results came "significantly" ahead of expectations and the upside flowed through to its 2025 guidance, Dove said in the note. The company&#8217;s indication that it is accelerating trends into May and June suggests the guidance is "somewhat conservative," she added.
The analyst continued to cite Carnival as among her top picks. "While the macro/geopolitical environment remains murky, CCL's exposure to primarily local Europe exposure and higher exposure to drive-to/shorter itineraries from the U.S. should provide some buffer to these headwinds," she further wrote.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Stifel On Carnival
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e84a1b9387cff00014945da/steven-wieczynski">Analyst Steven M. Wieczynski</a> reaffirmed a Buy rating and raised the price target from $33 to $34.
Carnival reported gross and net revenue of $6.3 billion and $4.9 billion, ahead of the consensus of $6.2 billion and $4.8 billion, respectively, Wieczynski said. Management raised their full-year guidance for adjusted earnings from $1.83 per share to $1.97 per share and for adjusted EBITDA from $6.7 billion to $6.9 billion, he added.
While investors have been nervous about cruise demand going into 2026, given the highly uncertain consumer spending environment, Carnival's latest commentary should help alleviate those concerns, especially since the company's 2026 bookings are close to record levels, the analyst stated. Investors still seem to be "overlooking the significant FCF generation that is currently being produced which will help delever CCL's balance sheet," he further wrote.
CCL Price Action: Shares of Carnival were down 0.9% to $25.46 at the time of publication on Wednesday.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46096528/nasdaq-100-record-highs-rally-historical-performance">Nasdaq 100 Hits Record Highs After 30% Rally: History Suggests It&#8217;s Not Done Yet</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings

Earnings Beats

Trading Ideas

Carnival's Booking Surge Has Wall Street Talking 2026 Already

Metalla Royalty & Streaming shares are trading higher after the company announced a credit facility of up to $75 million.

Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) has outperformed the market over the past 5 years by 16.45% on an annualized basis producing an average annual return of 30.96%. Currently, Oracle has a market capitalization of $597.73 billion. 
Buying $1000 In ORCL: If an investor had bought $1000 of ORCL stock 5 years ago, it would be worth $3,885.59 today based on a price of $212.81 for ORCL at the time of writing.
<h3>Oracle's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750865432_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORCL

Here's How Much $1000 Invested In Oracle 5 Years Ago Would Be Worth Today

NuScale Power shares are trading lower after BTIG downgraded the stock from Buy to Neutral.

The Metals Company shares are trading higher after Wedbush upgraded the stock from Neutral to Outperform and raised its price target from $6 to $11.

Conagra Brands shares are trading lower after the company announced it will complete the removal of certified food, drug , and cosmetic colors from its U.S. frozen product portfolio by the end of 2025.

Paychex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>)&nbsp;shares are&nbsp;trading lower on Wednesday&nbsp;after reporting <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46093321/paychex-inc-reports-fourth-quarter-and-full-year-2025-results" rel="noreferrer noopener">fiscal fourth-quarter 2025 earnings</a>.
The company reported quarterly revenue growth of 10% year-on-year to $1.43 billion, marginally missing the&nbsp;analyst consensus estimate of $1.44 billion.
The company reported an adjusted EPS of $1.19, which aligns with the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44519829/ai-investments-and-cost-savings-drive-paychexs-q3-profitability-surge-says-analyst" rel="noreferrer noopener">Paychex Analyst Sees Limited Upside Despite Q3 Profitability Surge</a>
Revenue from Management Solutions increased 12% to $1.0 billion, driven by the acquisition of Paycor.
The revenue from Professional Employer Organizations (PEO) and Insurance Solutions increased 4% to $340.3 million.
Total expenses increased 22% to $1.0 billion due to acquisition-related costs associated with the Paycor acquisition.
Operating income for the quarter decreased 11% to $431.1 million, and the operating margin declined 700 basis points to 30.2%.
Adjusted operating income&nbsp;grew 11% to $576.7 million, and the margin remained flattish at 40.4%. Excluding Paycor, the adjusted operating margin&nbsp;expanded by approximately 110 basis points compared to the prior year.
Adjusted EBITDA climbed 10% to $623.1 million, but the adjusted EBITDA margin remained flat. 
Paychex held $1.7 billion in total cash and equivalents as of May 31, 2025. The operating cash flow for the quarter totaled $400 million.
In a move to enhance shareholder value, Paychex bought back 828,855 shares for $104.0 million and paid out cumulative dividends totaling $1.4 billion at $4.02 per share over the fiscal year 2025.
<h2 class="wp-block-heading">Fiscal 2026 Outlook</h2>
Paychex expects fiscal revenue of $6.49 billion-$6.60 billion versus the $6.36 billion <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst consensus estimate</a>. It projects fiscal adjusted EPS of $5.40-$5.50 versus the $5.31 analyst consensus estimate. The company expects a fiscal adjusted operating margin of ~43%.
Price Action: PAYX shares are trading lower by 9.33% at $138.04 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46079632/bofa-sees-155-billion-agentic-ai-boom-by-2030-spotlights-microsoft-salesforce-and-others" target="_blank" rel="noreferrer noopener">BofA Sees $155 Billion Agentic AI Boom By 2030, Names Key Beneficiaries</a></li>
</ul>
Photo via Shutterstock

Guidance

PAYX

Paychex Stock Takes A Hit As Margin Squeeze Overshadows Outlook

Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) CEO Vlad Tenev on Tuesday expressed surprise at how resilient retail investors remained during the <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46070857/bitcoin-ethereum-xrp-dogecoin-consolidate-after-israel-iran-ceasefire-rally">recent Middle East tensions</a>.
What Happened: In a CNBC Squawk Box <a href="https://www.youtube.com/watch?v=R7Ukyc1Nd3U">interview</a> , Tenev stated that despite a weekend of escalating geopolitical risk, Robinhood&#8217;s platform saw no major shifts in retail trading behavior. 
"A year or two ago, an event like this would've caused big overnight moves. Now, it's barely a blip," Tenev said.
Retail traders continued their aggressive bets on high-growth sectors like AI, notably Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), crypto, and fintech, echoing trends from earlier months.
According to Tenev, Robinhood's 26 million U.S. users are still showing strong activity, with trading volumes remaining high and little impact from geopolitical headlines.
Robinhood has also expanded into prediction markets, debuting with U.S. presidential election markets last year and recently adding economic and sports bets through new partnerships. 
Tenev sees Robinhood's edge as offering retail-scale access to emerging markets: "We're just giving our massive user base what they want: early access to new and interesting markets," he said.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46081761/bitcoin-dominance-tops-65-but-altcoin-season-is-close-trader-says">Bitcoin Dominance Tops 65% But &#8216;Altcoin Season&#8217; Is Close, Trader Says</a>
Why It Matters: Tenev reiterated that regulatory clarity is the biggest missing ingredient for U.S. crypto innovation. 
He pointed to pending legislation that would allow crypto exchanges to register under the CFTC, rather than being scrutinized by the SEC.
"All the high-potential crypto innovation has been pushed overseas. It's rare that America lags in frontier innovation—but here we are," he said. "Europe is ahead of the U.S. right now." 
Robinhood is preparing to host its first major international crypto event in southern France, a move aimed at tapping into Europe's more favourable regulatory environment.
Looking forward, Tenev envisions crypto technology becoming the infrastructure for all financial services, not just crypto-specific assets. 
"Eventually, crypto rails will support everything, from stock trading to traditional finance," he predicted.
Robinhood's stock currently trades near $82, with a market cap around $72.4 billion. Tenev remains optimistic about long-term growth, citing tailwinds from AI, policy shifts, and increasing retail sophistication.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46091840/bitcoin-ethereum-xrp-dogecoin-hold-gains">Bitcoin, Ethereum, XRP, Dogecoin Hold Gains As Crypto ETF Inflows Continue</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

HOOD

TSLA

Robinhood CEO Highlights Retail Investor Interest In Nvidia, Tesla Despite Middle East Tensions: 'Barely A Blip'

CRWV

CoreWeave shares are trading lower. HC Wainwright & Co. initiated coverage on the stock with a Neutral rating.

TD Cowen analyst Jason Seidl maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Buy and lowers the price target from $310 to $269.

TD Cowen Maintains Buy on FedEx, Lowers Price Target to $269

Kandal M Venture Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMFC#NASDAQ">FMFC</a>) (the "Company"), a contract manufacturer of affordable luxury leather goods with manufacturing operations in Cambodia, announced the pricing of its initial public offering (the "Offering") of 2,000,000&nbsp;Class&nbsp;A ordinary shares (the "Class A Ordinary Shares") which was conducted on June 24, 2025, at a public offering price of $4.00 per Class A Ordinary Share (the "Offering Price"). The Class A Ordinary Shares are expected to begin trading on the Nasdaq Capital Market on June 25, 2025, under the symbol "FMFC."
The Offering is expected to close on June 26, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds for (i) broadening its customer base by expanding its geographical reach to other key markets, including the European markets, (ii) enhancing its production capacity, (iii) establishing a new design and development center for enhancing its product development capabilities, and (iv) additional working capital and other general corporate purposes.
In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 Class A Ordinary Shares of the Company, at the Offering Price, less underwriting discounts.

IPOs

FMFC

Kandal M Venture Prices IPO Of 2M Class A Ordinary Shares At $4.00/Shr

TD Cowen analyst Gautam Khanna maintains General Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) with a Buy and raises the price target from $290 to $300.

TD Cowen Maintains Buy on General Dynamics, Raises Price Target to $300

Health Care

Press Releases

General

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

Comments

Cabaletta Bio

Vendite allo scoperto

Cabaletta Bio (NASDAQ:CABA) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO